IrelandIreland

Elan finds biomarker to monitor Alzheimer’s plaques

02.03.2010

Dublin – The Elan Corporation has established a novel biomarker, 11C-PiB PET, that can detect whether Alzheimer drug candidates can reduce pathogenic beta-amyloid plaques in the brains of patients. With the new marker, Elan demonstrated in a phase II study on 28 patients that J&J’s/Janssen Cilag’s anti-beta-amyloid mAB bapineuzumab reduced cortical fibrillar amyloid-ß load in vivo after 78 weeks of treatment (Lancet Neurology) compared with both baseline and placebo. The technology used in the study could “play a major role in Alzheimer’s research and future clinical trial designs,” said Dr. Menghis Bairu, Elan’s chief medical officer. J&J had acquired Elan’s Alzheimer’s Immunotherapy Program (AIP) in 2008, which includes bapineuzumab IV and sub-cutaneous formulations, ACC-001 and backup compounds. Under the terms of the agreement Elan had received a 49.9% equity interest in Janssen Alzheimer Immunotherapy, Johnson & Johnson’s subsidiary that runs the programme.

IrelandIreland

21.09.2011

Palo Alto/Dublin - Jazz Pharmaceuticals Inc. has bought Azur Pharma Limited in an all-stock deal that will create a specialty pharmaceutical company incorporated in Ireland. Shareholders of Jazz will own nearly 80 percent of the...

IrelandIreland

26.05.2011

Dublin – Ireland’s Elan Corporation plc has paid US$50m to access Proteostasis Therapeutics’ pipeline of proteostasis regulators, peptidomimetic compounds that regulate protein folding, protein aggregation and protein degradation...

IrelandIreland

06.02.2011

Dublin – Irish drug maker Elan Corp. plc announced it has reduced its headcount by 130 (10%) to about 1,200. Elan said a nearly half of the 130 cuts came from the firm’s R&D department, and primarily occurred at its site in San...

IrelandIreland

07.09.2010

Nottingham/Dublin – Irish researchers have identified a new target in S.aureus bacteria that cause progressive bone destruction. According to Tania Claro from Royal College of Surgeons, S. aureus makes use of its surface protein...

IrelandIreland

11.08.2010

Elan Corporation plans to advance ELND005 into phase III testing, despite data indicating that it missed the co-primary endpoints in a phase II AD201 trial for Alzheimer's. According to the trial results, ELND005, a small...

IrelandIreland

03.08.2010

Dublin/St. Paul – Irish researchers have reported that a specific gene variant may increase the severity of multiple sclerosis (MS) symptoms. For the study, which was published in Neurology (3rd August), the research team led by...

IrelandIreland

20.04.2010

Dublin – Irish neuroscience specialist Elan Corporation plc has announced it is investigating the option of spinning out its Elan Drug Technologies business, creating two publicly listed enterprises. Elan is currently assessing...

IrelandIreland

17.12.2009

Dublin – Irish company Elan Corporation plc and its partner Transition Therapeutics have withdrawn patients from two ongoing phase II trials with the compound ELDN005 following the death of nine patients. The studies were stopped...

Displaying results 11 to 20 out of 49

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/1/article/elan-finds-biomarker-to-monitor-alzheimers-plaques.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events